IMAGIN MEDICAL update...

originally published Saturday, January 28, 2017

Printable Version

All Misc Articles

The purpose of this brief update is to point out that the technical condition of Imagin Medical continues to improve. You may recall that we looked at it back early in December when we saw that the stock looked like it was basing in readiness for a new bullmarket phase. Since then it has continued to trundle sideways in a narrow range at a low level, with a preponderance of upside volume which is bullish, but yesterday it rallied quite sharply on record turnover, a sign that things are hotting up.

Chart courtesy of stockwatch.com


As we see the price and its moving averages are starting to bunch together. This and the stronger upside volume point to a breakout above the 200-day moving average soon that will usher in a new bullmarket.

We will therefore aim to continue accumulating this stock on down days.

Imagin Medical website

Imagin Medical, IME (Canada), IMEXF on OTC, closed at C$0.095, $0.07 on 27th January 17.


Posted at 1.30 pm EST on 28th January 17.

The above represents the opinion and analysis of Mr Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. Mr. Maund is an independent analyst who receives no compensation of any kind from any groups, individuals or corporations mentioned in his reports. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stockmarket analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on the market and stocks can only be construed as a solicitation to buy and sell securities when they are subject to the prior approval and endorsement of a Registered Securities Advisor operating in accordance with the appropriate regulations in your area of jurisdiction.